The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Impaired Inflammatory Responses in Murine Lrrk2-Knockdown Brain Microglia
Open accessAbstract
LRRK2, a Parkinson's disease associated gene, is highly expressed in microglia in addition to neurons; however, its function in microglia has not been evaluated. Using Lrrk2 knockdown (Lrrk2-KD) murine microglia prepared by lentiviral-mediated transfer of Lrrk2-specific small inhibitory hairpin RNA (shRNA), we found that Lrrk2 deficiency attenuated lipopolysaccharide (LPS)-induced mRNA and/or protein expression of inducible nitric oxide synthase, TNF-α, IL-1β and IL-6. LPS-induced phosphorylation of p38 mitogen-activated protein kinase and stimulation of NF-κB-responsive luciferase reporter activity was also decreased in Lrrk2-KD cells. Interestingly, the decrease in NF-κB transcriptional activity measured by luciferase assays appeared to reflect increased binding of the inhibitory NF-κB homodimer, p50/p50, to DNA. In LPS-responsive HEK293T cells, overexpression of the human LRRK2 pathologic, kinase-active mutant G2019S increased basal and LPS-induced levels of phosphorylated p38 and JNK, whereas wild-type and other pathologic (R1441C and G2385R) or artificial kinase-dead (D1994A) LRRK2 mutants either enhanced or did not change basal and LPS-induced p38 and JNK phosphorylation levels. However, wild-type LRRK2 and all LRRK2 mutant variants equally enhanced NF-κB transcriptional activity. Taken together, these results suggest that LRRK2 is a positive regulator of inflammation in murine microglia, and LRRK2 mutations may alter the microenvironment of the brain to favor neuroinflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Hayden, M. S., & Ghosh, S. (2004) · Genes & Development · doi:10.1101/gad.1228704 · Cited by 3,842
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Toll-like Receptor-4 Mediates Lipopolysaccharide-induced Signal Transduction
Chow, J. C., Young, D. W., Golenbock, D. T., Christ, W. J., & Gusovsky, F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.16.10689 · Cited by 1,924
Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., & Przedborski, S. (1999) · Nature Medicine · doi:10.1038/70978 · Cited by 1,046 · cited 1×
“It has been reported that activated microglia expressing a large number of inflammatory genes are elevated in the striatum and SN region of PD patients and in animal models of PD, and mediate dopaminergic neuronal death [12,14,15].”
BackgroundKinase activity of mutant LRRK2 mediates neuronal toxicity
Smith, W. W., Pei, Z., Jiang, H., Dawson, V. L., Dawson, T. M., & Ross, C. A. (2006) · Nature Neuroscience · doi:10.1038/nn1776 · Cited by 619 · cited 1×
“Although there is evidence showing that expression of pathological LRRK2 mutations is sufficient to cause neurotoxicity in vitro [5,6], transgenic LRRK2 mutant mice show little or no obvious degeneration of dopaminergic neurons [7–10].”
BackgroundPott Godoy, M. C., Tarelli, R., Ferrari, C. C., Sarchi, M. I., & Pitossi, F. J. (2008) · Brain · doi:10.1093/brain/awn101 · Cited by 335 · cited 1×
“In addition, central and systemic IL-1 expression in an animal model was shown to enhance 6-hydroxydopamine-mediated neurodegeneration in the SN [61].”
BackgroundBachstetter, A. D., Xing, B., de Almeida, L., Dimayuga, E. R., Watterson, D. M., & Van Eldik, L. J. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-79 · Cited by 282
Cited by
Neuroinflammation in Parkinson's disease and its potential as therapeutic target
Wang, Q., Liu, Y., & Zhou, J. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0042-0 · Cited by 884
The Role of Astrocyte Dysfunction in Parkinson’s Disease Pathogenesis
Booth, H. D. E., Hirst, W. D., & Wade-Martins, R. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.04.001 · Cited by 633
Microglia and astrocyte dysfunction in parkinson's disease
Kam, T.-I., Hinkle, J. T., Dawson, T. M., & Dawson, V. L. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105028 · Cited by 389
Microglia Mediated Neuroinflammation in Parkinson’s Disease
Isik, S., Yeman Kiyak, B., Akbayir, R., Seyhali, R., & Arpaci, T. (2023) · Cells · doi:10.3390/cells12071012 · Cited by 379
Glutamate-induced excitotoxicity in Parkinson's disease: The role of glial cells
Iovino, L., Tremblay, M. E., & Civiero, L. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.07.011 · Cited by 374
Neurodegeneration and Inflammation—An Interesting Interplay in Parkinson’s Disease
Marogianni, C., Sokratous, M., Dardiotis, E., Hadjigeorgiou, G. M., Bogdanos, D., & Xiromerisiou, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228421 · Cited by 366
Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson’s disease
Taylor, J. M., Main, B. S., & Crack, P. J. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.12.016 · Cited by 303
Microglial phenotypes in Parkinson’s disease and animal models of the disease
Joers, V., Tansey, M. G., Mulas, G., & Carta, A. R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.006 · Cited by 285
The Contribution of Microglia to Neuroinflammation in Parkinson’s Disease
Badanjak, K., Fixemer, S., Smajić, S., Skupin, A., & Grünewald, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094676 · Cited by 276
Shao, F., Wang, X., Wu, H., Wu, Q., & Zhang, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.825086 · Cited by 250
The role of the LRRK2 gene in Parkinsonism
Li, J.-Q., Tan, L., & Yu, J.-T. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-47 · Cited by 249
“This suggested LRRK2 to be a positive regulator of inflammation in murine microglia, and LRRK2 mutations may alter the microenvironment of the brain to favor neuroinflammation [68].”
BackgroundInflammation is genetically implicated in Parkinson’s disease
Dzamko, N., Geczy, C. L., & Halliday, G. M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.10.028 · Cited by 222
Microglia in Parkinson's disease
Ho, M. S. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-13-9913-8_13 · Cited by 227
Takagawa, T., Kitani, A., Fuss, I., Levine, B., Brant, S. R., Peter, I., Tajima, M., Nakamura, S., & Strober, W. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan8162 · Cited by 145
“However, our findings are supported by previous reports showing that BMDMs from Lrrk2 KO mice exhibited no changes in cytokine production or NF-B expression when subjected to TLR ligand stimulation (38, 39) and that microglial cells subjected to Lrrk2 knockdown exhibited decreased TLR ligand–induced cytokine producti…”
BackgroundResultLRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase
Choi, I., Kim, B., Byun, J.-W., Baik, S. H., Huh, Y. H., Kim, J.-H., Mook-Jung, I., Song, W. K., Shin, J.-H., Seo, H., et al. (2015) · Nature Communications · doi:10.1038/ncomms9255 · Cited by 112
Self-citationKim, J.-H., Choi, D.-J., Jeong, H.-K., Kim, J., Kim, D. W., Choi, S. Y., Park, S.-M., Suh, Y. H., Jou, I., & Joe, E.-H. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.08.007 · Cited by 102
Self-citationIncreased peripheral inflammation in asymptomatic leucine‐rich repeat kinase 2 mutation carriers
Dzamko, N., Rowe, D. B., & Halliday, G. M. (2016) · Movement Disorders · doi:10.1002/mds.26529 · Cited by 98
Main, B. S., Zhang, M., Brody, K. M., Ayton, S., Frugier, T., Steer, D., Finkelstein, D., Crack, P. J., & Taylor, J. M. (2016) · Glia · doi:10.1002/glia.23028 · Cited by 92
Marker, D. F., Puccini, J. M., Mockus, T. E., Barbieri, J., Lu, S.-M., & Gelbard, H. A. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-261 · Cited by 90
“Recent studies have implicated LRRK2 in neuroinflammation and microglial inflammatory responses [18,21,30].”
BackgroundInfluentialLRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies
Kim, C., Beilina, A., Smith, N., Li, Y., Kim, M., Kumaran, R., Kaganovich, A., Mamais, A., Adame, A., Iba, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay0399 · Cited by 79
Cebrián, C., Loike, J. D., & Sulzer, D. (2014) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2014_356 · Cited by 65
Leucine-rich repeat kinase 2 (LRRK2) regulates α-synuclein clearance in microglia
Maekawa, T., Sasaoka, T., Azuma, S., Ichikawa, T., Melrose, H. L., Farrer, M. J., & Obata, F. (2016) · BMC Neuroscience · doi:10.1186/s12868-016-0315-2 · Cited by 59
Genetic Defects and Pro-inflammatory Cytokines in Parkinson's Disease
Magnusen, A. F., Hatton, S. L., Rani, R., & Pandey, M. K. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.636139 · Cited by 47
Lopez de Maturana, R., Aguila, J. C., Sousa, A., Vazquez, N., del Rio, P., Aiastui, A., Gorostidi, A., Lopez de Munain, A., & Sanchez-Pernaute, R. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.11.018 · Cited by 38
Fenner, B. M., Fenner, M. E., Prowse, N., & Hayley, S. P. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30588 · Cited by 14
“Microglia with the G2019S LRRK2 mutation are associated with increased inflammatory states, while LRRK2 inhibition can reduce inflammation and neurotoxicity (Daher et al., 2014; Gillardon et al., 2012; B. Kim et al., 2012; Moehle et al., 2012).”
Background
Metadata
- Authors
- Kim, B., Yang, M.-S., Choi, D., Kim, J.-H., Kim, H.-S., Seol, W., Choi, S., Jou, I., Kim, E.-Y., & Joe, E.-H.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-04-09
- Volume
- 7
- Issue
- 4
- Pages
- e34693
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2043857341
- Cited by
- 203
- References
- 8
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.